Skip to Content Skip to Content
Attorney General of Virginia Header

View Office of the Attorney General Expenditures



Lock Up Your Meds
News for CitizensOcwen MortgageMortgage Servicing Settlement Agreement
Computer Crime
Human Trafficking
Gang Prevention
Drug Take Back Program Line of Duty Death Claims
Medicaid Fraud
Elder Abuse and Neglect
TRIAD - Seniors
Official Opinions


State Seal
Commonwealth of Virginia
Office of the Attorney General

name and titleaddress



For media inquiries only, contact:  Brian J. Gottstein
Email: (best contact method)
Phone: 804-786-5874


Attorney General Cuccinelli announces settlement with Texas-based pharmaceutical manufacturer for illegal marketing of Xenaderm

~Virginia's Medicaid program to receive more than $223,000 in settlement~

RICHMOND (February 27, 2013) - Today, Attorney General Ken Cuccinelli announced that his office has reached a settlement with Texas-based pharmaceutical manufacturer Healthpoint, Ltd. and its general partner, DFB Pharmaceuticals, for the illegal marketing of Xenaderm, a topical treatment for skin ulcers. The attorney general said that the agreement will resolve allegations that Healthpoint submitted false claims to Virginia's Medicaid program for the unapproved drug. 

The settlement resolves federal and state False Claims Act cases brought against Healthpoint in the U.S. Federal District Court in Massachusetts. The cases were brought by the U.S. Department of Justice and fifteen plaintiff states.  As part of a $48 million settlement announced by the Department of Justice on December 6, 2012, Healthpoint and DFB will pay approximately $33 million total to settle Medicaid-based claims nationally.  The settlement will return $223,283.17 to the commonwealth's Medicaid program.

The federal and state complaints alleged Healthpoint marketed Xenaderm without FDA approval by modeling it on a pre-1962 drug that the FDA had never reviewed. Additionally, Healthpoint marketed the drug in spite of the FDA's determination in the 1970s that Xenaderm's principal ingredient was "less-than-effective" for its intended use.  Since 1981, federal health care programs, including Medicaid, have not paid for "less-than-effective" drugs or drugs "identical, related, or similar" to "less-than-effective" drugs.  According to the federal and state complaints, Healthpoint still misrepresented the regulatory status of Xenaderm when it submitted quarterly reports to the government and, as a result, knowingly submitted false Xenaderm claims to Medicaid programs.

A National Association of Medicaid Fraud Control Units (NAMFCU) team participated in the settlement negotiations with Healthpoint on behalf of the settling states.  Team members included representatives from attorney general's offices of Virginia, Florida, North Carolina, Ohio, and Massachusetts.  Assistant Attorney General Megan L. F. Holt served on the NAMFCU Settlement Team. 

**The claims settled by this agreement are allegations only; there has been no determination of liability.

More about Attorney General Cuccinelli

Photos of the attorney general

A copy of this news release may be found on the attorney general's web site here.

Like us on FacebookFollow us on TwitterFind us on PinterestView our videos on YouTube View our photos on flickr